POMPANO BEACH, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc.
(OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will initiate a nationwide launch of Vendaje AC ® with Venture Medical, LLC , the Company’s exclusive sales and marketing partner. The launch is scheduled to commence in the fourth quarter and will cover every Medicare Administrative Contractor (MAC) region across the United States. Jason Matuszewski, CEO of BioStem Technologies Inc.
, commented: “This is a pivotal moment for BioStem Technologies. With nationwide Medicare reimbursement, Vendaje AC ® becomes our second product available to patients across all 50 states. The launch of Vendaje AC ® underscores our commitment to delivering innovative wound care solutions for patients suffering from chronic, non-healing wounds.
We're excited to collaborate with Venture Medical once again, whose partnership was instrumental in the success of AmnioWrap2 ® . Together, we’re expanding access to cutting-edge treatments that make a real difference in patient outcomes.” John Schroeder, CEO of Venture Medical, LLC, added: “With countless graft products available today, we’re proud to partner with BioStem Technologies, a company that prioritizes clinical efficacy in everything they do.
Vendaje AC ® , manufactured using the innovative BioREtain ® process, retains the critical .